Stocks and Investing
Stocks and Investing
Mon, March 4, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, March 1, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Geoff Meacham Maintained (UTHR) at Sell with Decreased Target to $95 on, Mar 1st, 2019
Geoff Meacham of Barclays, Maintained "United Therapeutics Corporation" (UTHR) at Sell with Decreased Target from $100 to $95 on, Mar 1st, 2019.
Geoff has made no other calls on UTHR in the last 4 months.
There are 2 other peers that have a rating on UTHR. Out of the 2 peers that are also analyzing UTHR, 1 agrees with Geoff's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jessica Fye of "JP Morgan" Maintained at Hold with Increased Target to $126 on, Friday, November 2nd, 2018
This is the rating of the analyst that currently disagrees with Geoff
- M. Auster of "Credit Suisse" Maintained at Sell with Increased Target to $105 on, Monday, November 19th, 2018
Contributing Sources